ClinicalTrials.gg
WithdrawnNCT05244473Updated Feb 14, 2023

A Safety Study of Brentuximab Vedotin in Participants With HIV

A Phase 1 interventional study of brentuximab vedotin and Placebo in Human Immunodeficiency Virus, sponsored by Seagen Inc.. Withdrawn at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-14.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Study withdrawn due to low patient accrual.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will test brentuximab vedotin to see if it is safe for people with human immunodeficiency virus (HIV) who have low CD4+ and have received antiretroviral therapy (ART) treatment. It will also see if brentuximab vedotin raises CD4+ counts. It will study the side effects of this drug as well. A side effect is anything a drug does to the body besides treating the disease.

In this study participants will be assigned randomly to a group. Participants will get either brentuximab vedotin or placebo. A placebo looks like the drug but does not contain any medicine in it. All participants will keep getting ART during the study.

02

Conditions studied

  • Human Immunodeficiency Virus

Browse trials for

Keywords

  • HIV
  • Immunological Nonresponder
  • Seattle Genetics
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.

Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.

First submitted before Seagen Inc. became part of Pfizer.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -1 seropositive with documentation of infection
  • Immunological nonresponder, defined as:

    • Has been on ART with an HIV viral load \<50 copies/mL for at least 24 months
    • Has a CD4+ T-cell lymphocyte count between 51 to 200 cells/µL
  • of >9 months.
  • Participant is negative for , or if infected with hepatitis B, receiving anti-hepatitis B therapy
  • Participants with a history of virus (HCV) are eligible if they have completed therapy for HCV and show sustained virologic remission (12 weeks or more)

Exclusion criteria

Exclusion Criteria:

  • Any currently active AIDS-defining illness per Category C conditions according to the CDC Classification System for Infection, with the following exceptions:

    • Limited cutaneous Kaposi's sarcoma not currently requiring systemic therapy
    • Wasting syndrome due to HIV or any other AIDS-defining illness for which no therapeutic treatment is required OR the required treatment is not included in the list of prohibited medications
  • Acute liver disease or any other active infection secondary to HIV requiring acute therapy
  • History of progressive multifocal leukoencephalopathy (PML)
  • Prior clinical John Cunningham virus (JCV) infection, history of JCV identified in cerebrospinal fluid, or presence of JCV antibodies at screening
  • Cirrhosis secondary to any cause
  • Any immunomodulating therapy (excluding premedication ) within 4 weeks prior to the screening visit
  • Prior within 2 years other than cutaneous basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, anal intraepithelial neoplasia, or cutaneous Kaposi's sarcoma
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Brentuximab vedotin + ART

    Brentuximab vedotin given on Day 1 and Day 15. ART will be given throughout the study.

    Drug: brentuximab vedotin · Drug: ART

  • Placebo comparator
    Placebo + ART

    Placebo given on Day 1 and Day 15. ART will be given throughout the study.

    Drug: Placebo · Drug: ART

Interventions

  • Given into the vein (IV; intravenously)

    Also known as: ADCETRIS

  • DrugPlacebo

    Given by IV

  • DrugART

    Daily use of a combination of HIV medicines

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment

    Time frame: Through 30 days after last study treatment

  2. Number of participants with laboratory abnormalities

    Time frame: Approximately 1 year

  3. Number of participants with dose-limiting toxicities (DLTs) by dose level

    Time frame: Up to 30 days

Secondary outcomes

  1. Area under the concentration-time curve (AUC)

    Pharmacokinetic (PK) Parameter

    Time frame: Approximately 4 months

  2. Maximum concentration (Cmax)

    PK Parameter

    Time frame: Approximately 4 months

  3. Time to maximum concentration (Tmax)

    PK Parameter

    Time frame: Approximately 4 months

  4. Apparent terminal half-life (t1/2)

    PK Parameter

    Time frame: Approximately 4 months

  5. Trough concentration (Ctrough)

    PK Parameter

    Time frame: Approximately 4 months

  6. Incidence of antidrug antibodies (ADAs)

    Time frame: Approximately 4 months

  7. Proportion of participants with CD4+ T-cell lymphocyte count >200 cells/µL

    Time frame: Approximately 1 year

  8. Proportion of participants with CD4+ T-cell lymphocyte count >200 cells/µL, with a minimum increase of 50 cells/µL

    Time frame: Approximately 1 year

  9. Duration of CD4+ T-cell lymphocyte count increases >200 cells/µL

    The time from start of the first occurrence of CD4+ T-cell count increases to the level \>200 cells/µL to the first occurrence of CD4+ T-cell count to the level \<200 cells/µL

    Time frame: Approximately 1 year

  10. Duration of CD4+ T-cell lymphocyte count increases >200 cells/µL with a minimum increase of 50 cells/µL

    The time from start of the first occurrence of CD4+ T-cell count increases to the level \>200 cells/µL to the first occurrence of CD4+ T-cell count to the level \<200 cells/µL with a minimum increase of 50 cells/µL

    Time frame: Approximately 1 year

  11. Change from baseline in CD4+ T-cell lymphocyte counts

    The change from baseline in CD4+ T-cell lymphocyte counts will be summarized based on observed values.

    Time frame: Approximately 1 year

  12. Change from baseline in CD4+ T cell percentage

    The change from baseline in CD4+ T cell percentage will be summarized based on observed values.

    Time frame: Approximately 1 year

  13. Change from baseline in CD8+ T-cell lymphocyte counts

    The change from baseline CD8+ T-cell lymphocyte counts will be summarized based on observed values.

    Time frame: Approximately 1 year

  14. Change from baseline in CD4:CD8 ratio

    The change from baseline in CD4:CD8 ratio will be summarized.

    Time frame: Approximately 1 year

  15. Change from baseline in Treg and other T-cell subsets

    Time frame: Approximately 6 months

  16. Proportion of subjects with HIV viral load <50 copies/mL

    The proportion of subjects with HIV viral load \<50 copies/mL will be summarized.

    Time frame: Approximately 1 year

  17. Proportion of subjects with fatal or non-fatal acquired immunodeficiency syndrome (AIDS) related opportunistic disease or death from any cause

    Time frame: Approximately 1 year

07

Study locations

2 sites
  • University of California at San Francisco
    San Francisco, California 94110, United States
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2022; primary completion for May 2024, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2022
First posted
Feb 17, 2022
StartEst.
Dec 31, 2022
Primary completionEst.
May 31, 2024
CompletionEst.
May 31, 2024
Last update
Feb 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05244473
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Feb 17, 2022
Start date
Dec 31, 2022 (estimated)
Primary completion
May 31, 2024 (estimated)
Completion
May 31, 2024 (estimated)
Last update
Feb 14, 2023

Study contacts

Andrei Shustov, MD
study director · Seagen Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion